BTIG likes MannKind in premarket analyst action

|About: CymaBay Therapeutics, ... (CBAY)|By:, SA News Editor

CymaBay Therapeutics (NASDAQ:CBAY) initiated with Buy rating and $21 (70% upside) price target at Citigroup. Shares up 1% premarket.

MannKind (NASDAQ:MNKD) initiated with Buy rating and $3 (144% upside) price target at BTIG Research citing peak sales of more than $350M for Afrezza. Analyst Robert Hazlett also likes the potential upside with technosphere programs in migraine, cystic fibrosis and cannabinoids. Shares up 10% premarket.

Pieris Pharmaceuticals (NASDAQ:PIRS) initiated with Outperform rating and $5 (41% upside) price target at Baird.

Haemonetics (NYSE:HAE) upgraded to Outperform with a $110 (16% upside) price target at Raymond James.

TransEnterix (NYSEMKT:TRXC) upgraded to Buy with a $3 (136% upside) price target at BTIG. Shares up 4% premarket.

INSYS Therapeutics (NASDAQ:INSY) downgraded to Neutral with a $1 (5% upside) price target at Janney Montgomery. Shares down 15% premarket.

Solid Biosciences (NASDAQ:SLDB) downgraded to Underperform with a $6 (32% downside risk) price target at Credit Suisse after the company reported potential safety risks with DMD gene therapy. Shares down 44% premarket on average volume.

Subscribe for full text news in your inbox